A security analysis is not yet prepared for this market.
The series is stated in the current share scale after splits; dividends are not included in the price
IQVIA runs clinical trials for drug companies and sells pharmaceutical market data.
For a drug developer it is cheaper to hire a contractor than to maintain its own network of research sites: a trial requires hundreds of locations across countries, physician coordination and regulatory reporting. The company does this professionally and secures contracts years ahead.
The second part is data: prescription and drug sales information bought by the same pharmaceutical companies for planning. That is subscription revenue at high margins. Risks: reduced research budgets, especially at biotech start-ups dependent on raising capital. The trial backlog is the leading indicator, and it turns months before revenue does. The company pays no dividend.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
IQVIA Holdings, Inc. (IQV) is a company in the Health care sector; its shares trade on NYSE.
The price of IQVIA Holdings, Inc. (IQV) on November 3, 2026 is 262.43 $, +1.54 % on the day. Over 52 weeks the stock traded between 154.50 $ and 277.40 $; the price now sits 88 % of the way up that range. Over the past year the price changed by +33.44 %. The P/E ratio is 31.65, which is above the sector median (24.61). Market capitalization is 43.51 billion $, rank 1 among 10 stocks of the same industry with a known capitalization.
IQVIA Holdings, Inc. trades on NYSE under the ticker IQV. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks IQV has traded between 154.50 $ and 277.40 $. As of 3 November 2026 the price stood 94.83 % of the way from the 52-week low to the high.
Over one year IQV shares rose 33.44 %; over six months they rose 57.63 %. Volatility over 90 days is 38.25 %. Dividends are not included: this is price change only, as of 3 November 2026.
IQV trades at a price-to-earnings ratio of 31.6, above the sector median of 24.6. Price to sales is 2.6, below the sector median of 3.6. Price to book is 7.1, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
IQVIA Holdings, Inc. reported revenue of 17.0B $ and net income of 1.4B $ over the last four quarters. Net margin is 8.10 %. Revenue changed by +8.17 % year over year. Earnings per share are 8.04 $. Market capitalisation is 43.5B $.
IQV has a return on equity of 22.28 %, above the sector median of −40.58 %. Return on assets is 4.60 %, above the sector median of −30.08 %. Operating margin is 12.95 %, above the sector median of −20.96 %.
